Clovis Oncology Company Profile (NASDAQ:CLVS)

About Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology logoClovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CLVS
  • CUSIP: 18946410
  • Web:
  • Market Cap: $4.57699 billion
  • Outstanding Shares: 44,772,000
Average Prices:
  • 50 Day Moving Avg: $56.20
  • 200 Day Moving Avg: $56.21
  • 52 Week Range: $11.57 - $95.33
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -44.77
  • P/E Growth: -0.52
Sales & Book Value:
  • Annual Revenue: $7.12 million
  • Price / Sales: 593.98
  • Book Value: $3.89 per share
  • Price / Book: 24.28
  • EBIDTA: ($262,070,000.00)
  • Return on Equity: -322.29%
  • Return on Assets: -62.07%
  • Debt-to-Equity Ratio: 1.62%
  • Current Ratio: 7.29%
  • Quick Ratio: 7.17%
  • Average Volume: 1.87 million shs.
  • Beta: 1.73
  • Short Ratio: 5.15

Frequently Asked Questions for Clovis Oncology (NASDAQ:CLVS)

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

How were Clovis Oncology's earnings last quarter?

Clovis Oncology, Inc. (NASDAQ:CLVS) released its quarterly earnings results on Wednesday, May, 3rd. The company reported ($1.33) EPS for the quarter, topping the consensus estimate of ($1.43) by $0.10. The company had revenue of $7.05 million for the quarter, compared to analyst estimates of $6.04 million. View Clovis Oncology's Earnings History.

Where is Clovis Oncology's stock going? Where will Clovis Oncology's stock price be in 2017?

15 brokerages have issued 1 year price targets for Clovis Oncology's stock. Their forecasts range from $23.00 to $125.00. On average, they anticipate Clovis Oncology's stock price to reach $74.54 in the next year. View Analyst Ratings for Clovis Oncology.

What are analysts saying about Clovis Oncology stock?

Here are some recent quotes from research analysts about Clovis Oncology stock:

  • 1. Cann analysts commented, "We are initiating coverage of Clovis Oncology, a recently commercial-stage biotechnology company, with a Perform rating. We anticipate Clovis will continue to develop its commercial drug, Rubraca (already approved for third-line ovarian cancer), in additional indications. Rubraca (rucaparib) is a PARP inhibitor for the treatment of ovarian cancer. As a therapeutic class, PARP inhibitors—including FDA-approved Lynparza (olaparib) and Zejula (niraparib)—are designed to exploit a synthetically lethal situation in tumors that lack proper DNA repair mechanisms." (6/22/2017)
  • 2. Goldman Sachs Group, Inc. (The) analysts commented, "AZN (covered by Keyur Parekh) presented data from a Ph3 SOLO-2 maintenance ovarian cancer trial of Lynparza (PARP inhibitor) on March 14 at the SGO conference, which we believe has implications for CLVS (lead marketed drug Rubraca is also a PARP). CLVS, AZN and TSRO (not covered) all have PARP inhibitors that they are evaluating for use in the maintenance treatment of ovarian cancer." (3/15/2017)
  • 3. According to Zacks Investment Research, "Clovis got a huge boost with the FDA granting accelerated approval to its advanced ovarian cancer treatment, Rubraca. It is not only the first approved product in Clovis’ portfolio, but also has bright prospects given the immense commercial potential in the target market and the tremendous demand for PARP inhibitors. Successful commercialization will significantly boost Clovis’ top line, going forward. Rubraca is also under review in the EU for a comparable ovarian cancer indication. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. Meanwhile, Clovis is looking to expand Rubraca’s label into additional indication like prostrate, breast and pancreatic cancers, among others. Also, shares of Clovis outperformed the industry in the past one year. Estimates have been stable ahead of Q4 results. However, Clovis’ dependence on Rubraca alone for growth is a cause for concern." (2/8/2017)
  • 4. Stifel Nicolaus analysts commented, "This price assumes about a 40% market share for rucaparib throughout addressable ovarian cancer (OC). However, in deriving this target, we include sales in the maintenance setting for ovarian cancer with a weighting of 75% (some risk remains to ARIEL3) and note that full weighing of this unapproved usage would suggest a fair value of about $104. Furthermore, inclusion of sales in mCRPC, which we consider highly promising but where large trials are just starting, suggests a fair value for Clovis shares of about $182. We consider most of the ongoing trials for rucaparib to be relatively low risk, but with several other players also competing for each indication we believe a takeout price of about 50% of our best case scenario makes sense." (1/23/2017)
  • 5. J P Morgan Chase & Co analysts commented, "CLVS’ 2Q report this afternoon was fairly uneventful, though the co did note that rucaparib’s full NDA dataset had been accepted for presentation at ESMO (Oct 7- 11, Copenhagen), and that ARIEL3 data (rucap in maintenance) is now expected in 4Q17 following release of a similar data set from TSRO (though CLVS has no knowledge of the event rate in ARIEL3). While we do see potential value for rucap, we think it’s hard to differentiate between the PARPs at this stage, and we are maintaining our Neutral rating." (8/9/2016)

Are investors shorting Clovis Oncology?

Clovis Oncology saw a decrease in short interest in May. As of May 15th, there was short interest totalling 8,391,818 shares, a decrease of 0.2% from the April 28th total of 8,409,669 shares. Based on an average daily trading volume, of 1,820,021 shares, the short-interest ratio is presently 4.6 days.

Who are some of Clovis Oncology's key competitors?

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the folowing people:

  • M. James E. Barrett Ph.D., Independent Chairman of the Board
  • Patrick J. Mahaffy, President, Chief Executive Officer, Director
  • Daniel W. Muehl, Senior Vice President of Finance, Principal Accounting Officer and Principal Financial Officer
  • Gillian C. Ivers-Read, Executive Vice President - Technical Operations, Chief Regulatory Officer
  • Lindsey Rolfe BSc, MB ChB, MRCP, F, Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer
  • C. Dale Hooks, Senior Vice President, Chief Commercial Officer
  • Brian G. Atwood, Independent Director
  • James C. Blair Ph.D., Independent Director
  • Keith T. Flaherty M.D., Independent Director
  • Ginger L. Graham, Independent Director

Who owns Clovis Oncology stock?

Clovis Oncology's stock is owned by a number of of retail and institutional investors. Top institutional investors include Palo Alto Investors LLC (8.70%), Vanguard Group Inc. (7.33%), State Street Corp (4.16%), FMR LLC (4.06%), Wellington Management Group LLP (2.97%) and Boxer Capital LLC (2.23%). Company insiders that own Clovis Oncology stock include Erle T Mast, Gillian C Ivers-Read and Lindsey Rolfe. View Institutional Ownership Trends for Clovis Oncology.

Who sold Clovis Oncology stock? Who is selling Clovis Oncology stock?

Clovis Oncology's stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co. NY, Redmile Group LLC, State Street Corp, Goldman Sachs Group Inc., Blue Jay Capital Management LLC, Morgan Stanley, Jennison Associates LLC and UBS Group AG. View Insider Buying and Selling for Clovis Oncology.

Who bought Clovis Oncology stock? Who is buying Clovis Oncology stock?

Clovis Oncology's stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Wellington Management Group LLP, Alliancebernstein L.P., Vanguard Group Inc., Emerald Advisers Inc. PA, Bogle Investment Management L P DE, Boxer Capital LLC and Cibc World Markets Corp. View Insider Buying and Selling for Clovis Oncology.

How do I buy Clovis Oncology stock?

Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of Clovis Oncology stock can currently be purchased for approximately $94.46.

MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  278 (Vote Outperform)
Underperform Votes:  210 (Vote Underperform)
Total Votes:  488
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Clovis Oncology (NASDAQ:CLVS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $74.54 (21.09% downside)

Analysts' Ratings History for Clovis Oncology (NASDAQ:CLVS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/23/2017Oppenheimer Holdings, Inc.Initiated CoverageMarket PerformLowView Rating Details
6/22/2017CannInitiated CoverageMarket PerformLowView Rating Details
6/22/2017SunTrust Banks, Inc.Reiterated RatingBuyLowView Rating Details
6/20/2017J P Morgan Chase & CoReiterated RatingOverweight$72.00 -> $111.00HighView Rating Details
6/20/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$67.00 -> $90.00HighView Rating Details
6/20/2017Janney Montgomery ScottUpgradeNeutral -> BuyMediumView Rating Details
6/20/2017Bank of America CorporationLower Price TargetBuy$103.00 -> $75.00HighView Rating Details
6/20/2017Morgan StanleyReiterated RatingOverweight$79.00HighView Rating Details
6/19/2017Leerink SwannBoost Price TargetOutperform$85.00 -> $114.00HighView Rating Details
6/19/2017Stifel NicolausBoost Price TargetBuy$86.00 -> $125.00HighView Rating Details
6/19/2017Chardan CapitalUpgradeSell -> Neutral$36.00 -> $50.00HighView Rating Details
6/16/2017Credit Suisse GroupReiterated RatingOutperform -> Outperform$88.00MediumView Rating Details
3/28/2017Piper Jaffray CompaniesSet Price TargetBuy$77.00LowView Rating Details
12/21/2016WallachBeth CapitalBoost Price TargetHold$22.00 -> $49.00N/AView Rating Details
8/24/2016MizuhoBoost Price TargetNeutral$15.00 -> $23.00N/AView Rating Details
(Data available from 6/27/2015 forward)


Earnings History for Clovis Oncology (NASDAQ:CLVS)
Earnings by Quarter for Clovis Oncology (NASDAQ:CLVS)
Earnings History by Quarter for Clovis Oncology (NASDAQ CLVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q1 2017($1.43)($1.33)$6.04 million$7.05 millionViewListenView Earnings Details
2/22/2017Q416($1.65)($1.83)$0.08 millionViewListenView Earnings Details
11/3/2016Q316($1.95)($1.70)ViewListenView Earnings Details
8/8/2016Q216($2.13)($2.07)ViewListenView Earnings Details
5/5/2016Q116($2.39)($2.17)ViewListenView Earnings Details
2/25/2016Q415($2.39)($2.23)ViewListenView Earnings Details
11/5/2015Q315($2.07)($2.62)ViewListenView Earnings Details
8/6/2015Q215($2.11)($2.10)$1.17 millionViewListenView Earnings Details
5/6/2015Q115($1.78)($1.86)$13.60 millionViewListenView Earnings Details
2/25/2015Q414($1.41)($1.62)ViewListenView Earnings Details
11/6/2014Q314($1.03)($1.17)ViewListenView Earnings Details
8/7/2014Q214($0.93)($1.03)$13.60 millionViewListenView Earnings Details
5/8/2014Q114($0.85)($0.91)$13.60 millionViewListenView Earnings Details
2/27/2014Q4($0.78)($0.92)ViewListenView Earnings Details
10/31/2013Q313($0.68)($0.68)ViewListenView Earnings Details
8/1/2013Q2 2013($0.65)($0.72)ViewListenView Earnings Details
5/7/2013Q1 2013($0.60)($0.60)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Clovis Oncology (NASDAQ:CLVS)
2017 EPS Consensus Estimate: ($4.89)
2018 EPS Consensus Estimate: ($2.18)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.53)($1.53)($1.53)
Q2 20173($1.30)($1.18)($1.23)
Q3 20173($1.16)($1.05)($1.11)
Q4 20173($1.13)($0.87)($1.02)
Q1 20181($0.67)($0.67)($0.67)
Q2 20181($0.53)($0.53)($0.53)
Q3 20181($0.53)($0.53)($0.53)
Q4 20181($0.45)($0.45)($0.45)
(Data provided by Zacks Investment Research)


Dividend History for Clovis Oncology (NASDAQ:CLVS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Clovis Oncology (NASDAQ:CLVS)
Insider Ownership Percentage: 17.40%
Institutional Ownership Percentage: 90.67%
Insider Trades by Quarter for Clovis Oncology (NASDAQ:CLVS)
Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)
Insider Trades by Quarter for Clovis Oncology (NASDAQ:CLVS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/15/2017Gillian C Ivers-ReadInsiderSell3,000$61.82$185,460.00View SEC Filing  
5/15/2017Gillian C Ivers-ReadInsiderSell3,000$47.39$142,170.00View SEC Filing  
4/17/2017Gillian C Ivers-ReadInsiderSell3,000$56.02$168,060.00View SEC Filing  
3/15/2017Gillian C Ivers-ReadInsiderSell3,000$66.99$200,970.00View SEC Filing  
11/2/2015Erle T. MastCFOSell3,000$105.56$316,680.00View SEC Filing  
10/28/2015Lindsey RolfeinsiderSell4,000$98.02$392,080.00View SEC Filing  
10/15/2015Gillian C Ivers-ReadInsiderSell3,000$91.91$275,730.00View SEC Filing  
10/5/2015Lindsey RolfeinsiderSell4,000$93.04$372,160.00View SEC Filing  
10/1/2015Erle T. MastCFOSell3,000$90.22$270,660.00View SEC Filing  
9/18/2015Gillian C Ivers-ReadInsiderSell3,000$112.56$337,680.00View SEC Filing  
9/1/2015Erle T. MastCFOSell3,000$79.51$238,530.00View SEC Filing  
7/1/2015Erle T MastCFOSell3,000$85.70$257,100.00View SEC Filing  
6/1/2015Erle T MastCFOSell3,000$88.78$266,340.00View SEC Filing  
5/15/2015M James BarrettDirectorSell2,424$92.43$224,050.32View SEC Filing  
4/1/2015Erle T MastCFOSell3,000$71.25$213,750.00View SEC Filing  
3/9/2015Erle T MastCFOSell9,000$78.84$709,560.00View SEC Filing  
3/5/2015James C BlairDirectorSell8,528$77.70$662,625.60View SEC Filing  
1/16/2015Steven L HoerterInsiderSell10,000$67.00$670,000.00View SEC Filing  
12/11/2013Erle MastCFOSell50,000$52.78$2,639,000.00View SEC Filing  
12/5/2013Thorlef SpickschenDirectorSell9,000$56.10$504,900.00View SEC Filing  
6/5/2013Andrew R AllenInsiderSell22,594$68.54$1,548,592.76View SEC Filing  
6/4/2013M James BarrettDirectorSell2,483$70.80$175,796.40View SEC Filing  
6/4/2013Parters Vii L P DomainMajor ShareholderSell159,192$64.58$10,280,619.36View SEC Filing  
6/4/2013Steven L HoerterInsiderSell10,000$73.06$730,600.00View SEC Filing  
3/6/2013Parters Vii L P DomainMajor ShareholderSell250,000$24.59$6,147,500.00View SEC Filing  
8/16/2012Edward J MckinleyDirectorBuy9,701$15.50$150,365.50View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Clovis Oncology (NASDAQ:CLVS)
Latest Headlines for Clovis Oncology (NASDAQ:CLVS)
DateHeadline logoEquities Analysts Issue Forecasts for Clovis Oncology, Inc.'s Q2 2017 Earnings (CLVS) - June 26 at 7:08 AM logoClovis Oncology, Inc. (CLVS) to Post Q2 2017 Earnings of ($1.18) Per Share, Oppenheimer Holdings Forecasts - June 26 at 7:08 AM logoWhat To Expect From Clovis Oncology Following Rubraca Approval - Benzinga - June 24 at 3:02 AM logoHealthcare ETF (IYH) Hits New 52-Week High - June 23 at 4:58 PM logoWhat To Expect From Clovis Oncology Following Rubraca Approval - June 23 at 1:38 PM logoClovis Oncology, Inc. (CLVS) Earns Market Perform Rating from Analysts at Oppenheimer Holdings, Inc. - June 23 at 9:06 AM logoClovis Oncology (CLVS) Prices Upsized Offering at $88/Share - June 22 at 9:48 PM logoClovis Oncology, Inc. (CLVS) Coverage Initiated at Cann - June 22 at 5:27 PM logoClovis Oncology commencing $250 million stock offering - June 22 at 4:39 PM logoClovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock - June 22 at 11:05 AM logoClovis Oncology, Inc. (CLVS) Worth a Look: Stock Jumps 6.3% - June 22 at 11:05 AM logo$13.65 Million in Sales Expected for Clovis Oncology, Inc. (CLVS) This Quarter - June 22 at 10:24 AM logoSunTrust Banks, Inc. Reaffirms Buy Rating for Clovis Oncology, Inc. (CLVS) - June 22 at 10:22 AM logoBidaskClub Upgrades Clovis Oncology, Inc. (CLVS) to Buy - June 21 at 8:18 PM logoQ3 2017 EPS Estimates for Clovis Oncology, Inc. (CLVS) Lifted by Leerink Swann - June 21 at 8:36 AM logoClovis Oncology (CLVS) Prices Upsized Offering at $88/Share - - June 20 at 10:02 PM logoClovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock - June 20 at 10:02 PM logo Brokerages Expect Clovis Oncology, Inc. (CLVS) to Announce -$1.20 EPS - June 20 at 4:10 PM logoClovis Addresses Some Of The Company's Biggest Controversies - June 20 at 3:55 PM logoJ P Morgan Chase & Co Reiterates "Overweight" Rating for Clovis Oncology, Inc. (CLVS) - June 20 at 12:28 PM logoClovis Oncology, Inc. (CLVS) Stock Rating Upgraded by Janney Montgomery Scott - June 20 at 7:58 AM logoMid-Afternoon Market Update: Crude Oil Down Over 1%; Clovis Oncology Shares Spike Higher - Nasdaq - June 20 at 5:24 AM logoClovis Oncology Inc. (CLVS) Is Pulling Back After Stock Offering - June 20 at 12:23 AM logoBiotech stocks are having their best day since February - June 20 at 12:22 AM logoClovis Oncology Announces Proposed Offering of Common Stock - June 20 at 12:22 AM logoClovis Oncology to launch $250 mln stock offering - June 20 at 12:22 AM logoMid-Afternoon Market Update: Crude Oil Down Over 1%; Clovis Oncology Shares Spike Higher - Benzinga - June 19 at 7:22 PM logoWhy Clovis Oncology Inc (CLVS) Stock Just Shot 50% Higher - - June 19 at 7:22 PM logoHere's what's behind the biotech breakout - June 19 at 7:22 PM logoClovis Oncology Target of Unusually High Options Trading (CLVS) - June 19 at 5:38 PM logoClovis Oncology, Inc. (CLVS) Given New $114.00 Price Target at Leerink Swann - June 19 at 4:28 PM logoMid-Afternoon Market Update: Crude Oil Down Over 1%; Clovis Oncology Shares Spike Higher - June 19 at 4:22 PM logoClovis Oncology's Rubraca Notches Key Trial Win - June 19 at 2:34 PM logoBiotech Movers: Clovis, Seattle Genetics, Rigel - - June 19 at 2:19 PM logoPre-Market Most Active for Jun 19, 2017 : AEG, RICE, CLVS, AUY, QQQ, NVDQ, VRX, RIGL, HL, TSRO, KR, JD - Nasdaq - June 19 at 2:19 PM logoClovis Oncology Inc. (CLVS) Has Soared To A New High On Phase 3 Study Results - Nasdaq - June 19 at 2:19 PM logoClovis Oncology stock surges 50% on positive late-stage cancer trial results - MarketWatch - June 19 at 2:19 PM logo[$$] The Dark Side of Good News in Biotech - June 19 at 2:19 PM logoWhy Tesaro Inc. Stock Briefly Dipped Today - June 19 at 2:19 PM logoHere's Why Clovis Oncology (CLVS) Stock Skyrocketed Today - June 19 at 2:19 PM logoTesaro: Is The Selloff Overdone? - June 19 at 2:19 PM logoThis Biotech Flew 50% On Strong Trial — But Is Its Drug Really Better? - June 19 at 2:19 PM logoWhy Clovis Oncology Inc (CLVS) Stock Just Shot 50% Higher - June 19 at 12:33 PM logoStifel Nicolaus Raises Clovis Oncology, Inc. (CLVS) Price Target to $125.00 - June 19 at 12:20 PM logoWhy Clovis Oncology Stock Is Soaring Today - June 19 at 11:37 AM logoClovis Oncology, Inc. (CLVS) Upgraded to "Neutral" at Chardan Capital - June 19 at 9:46 AM logoClovis Oncology, Inc. (CLVS) Research Coverage Started at Leerink Swann - June 18 at 6:20 PM logoSurging Earnings Estimates Signal Good News for Clovis Oncology, Inc. (CLVS) - Nasdaq - June 16 at 10:05 PM logoHere's Why Clovis (CLVS) Stock is Up Almost 350% in One Year - June 16 at 5:04 PM logoClovis Oncology, Inc. (CLVS) Now Covered by Analysts at Credit Suisse Group - June 16 at 11:16 AM



Clovis Oncology (CLVS) Chart for Tuesday, June, 27, 2017

This page was last updated on 6/27/2017 by Staff